GLP / Metabolic

Semaglutide 5mg (GLP-1)

Synthetic peptide analog — 31 amino acids For receptor interaction and signaling pathway research Research-grade · Lyophilized powder For in vitro research only

$37.99 In stock
SSL 256-bit Secure Checkout
Same-day dispatch on orders before 12:00 PM ET, Mon–Fri. Discreet, plain packaging.
View this compound’s Certificate of Analysis →

For laboratory research use only. Not for human or veterinary consumption. SKU SM5.

Overview

Product details.

SM1 5mg — GLP-1 Receptor Agonist
Native GLP-1 lasts about two minutes in circulation before DPP-IV enzymes chew it apart. SM1 was engineered to survive. This 31-amino-acid analog carries a C18 fatty acid chain that lets it hitch a ride on serum albumin — a molecular trick that extends its functional half-life dramatically in experimental models while preserving full GLP-1 receptor affinity.
Research-Grade Compounds
Manufactured to research-grade standards for laboratory research use only.
Discreet Shipping
Every order ships in plain, protective packaging.
In-House Fulfillment
Orders are inspected, packed, and shipped directly by the Heritage Labs team.

The engineering behind it

Two problems had to be solved. First, resistance to DPP-IV cleavage — the enzyme that makes native GLP-1 nearly useless as a research tool due to its rapid degradation. Second, a way to extend circulation time without altering receptor binding. The C18 fatty acid acylation addresses both: it provides steric protection from enzymatic degradation and enables reversible, non-covalent albumin association that keeps the peptide in circulation far longer than the native hormone.

The receptor interaction itself is well-characterized. SM1 activates GLP-1 receptors on pancreatic beta cells, initiating a cAMP/PKA signaling cascade that drives glucose-dependent insulin secretion. The key phrase is glucose-dependent — GLP-1 receptor agonists work with existing glucose levels rather than forcing insulin release regardless of metabolic state.

Specifications

Amino Acids 31
Classification Selective GLP-1 receptor agonist
Modification C18 fatty acid acylation for albumin binding
Form Lyophilized powder
Quantity 5mg per vial

What the research shows

Hypothalamic appetite regulation

GLP-1 receptors are expressed in the arcuate nucleus and other appetite-regulating brain regions. Preclinical studies have examined how receptor agonism at these central sites modulates feeding behavior and energy balance through both peripheral and central signaling pathways.

Metabolic pathway studies

Research models have examined GLP-1 receptor activation in the context of glucose homeostasis, insulin sensitivity, hepatic glucose output, and overall energy balance as part of the broader incretin signaling axis.

Frequently paired with

  • Cagrilintide 5mg — Amylin analog. Amylin and GLP-1 act through distinct neuronal circuits (hindbrain vs hypothalamic), making them complementary research targets.
  • AOD-9604 5mg — HGH Fragment 176-191 for comparative metabolic research.
  • MOTS-C 10mg — AMPK pathway activation and cellular energy metabolism.

Quality and testing

Every Heritage Labs compound is manufactured to research-grade standards and shipped in protective packaging.

Storage

  • Lyophilized: -20°C for long-term stability
  • Reconstituted: 2-8°C, use within 30 days
  • Protection: Keep away from light and moisture

For laboratory research use only. Not for human or veterinary use.

For laboratory research use only. Not for human or veterinary use. This product is not a drug or supplement and is not intended to diagnose, treat, cure, or prevent any disease.

FDA Disclaimer. All products are for research use only (RUO) as defined by the FDA — not for diagnostic, human, or veterinary use. These products have not been evaluated and have not been approved by the U.S. Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

Heritage Labs is a chemical supplier providing products strictly for laboratory research, analytical, and in-vitro purposes; it is not a compounding pharmacy or compounding facility under Section 503A, nor an outsourcing facility under Section 503B, of the Federal Food, Drug, and Cosmetic Act.

Loading...